Fuente: PubMed "nature biotechnology" Trends Cancer. 2026 Jun 20:S2405-8033(26)00134-2. doi: 10.1016/j.trecan.2026.06.006. Online ahead of print.ABSTRACTThe Drug Rediscovery Protocol by K. Verkerk, et al., operationalized nationwide biomarker-guided, off-label precision oncology. Yet outcomes (15.7% response rate) mirror a decade of studies, indicating a single biomarker-drug strategy ceiling. Advancing efficacy will require customized, individualized combinations, consistent with the hallmarks of cancer complexity and the I-PREDICT (Investigation of profile-related evidence determining individualized cancer therapy) style clinical studies framework, which shows that outcomes scale with greater biomarker matching.PMID:42323272 | DOI:10.1016/j.trecan.2026.06.006